QCG
VIR icon

Quadrant Capital Group’s Vir Biotechnology VIR Stock Holding History

Quadrant Capital Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63K Hold
182
– – ﹤0.01% 2534
2025
Q4 		$1.1K Hold
182
– – ﹤0.01% 2589
2025
Q3 		$1.04K Buy
+182
New +$931 ﹤0.01% 2554
2025
Q1 		– Sell
-474
Closed -$3.48K – 2843
2024
Q4 		$3.48K Sell
474
-2,852
-86% -$22.5K ﹤0.01% 2389
2024
Q3 		$24.9K Sell
3,326
-776
-19% -$6.74K ﹤0.01% 1805
2024
Q2 		$36.5K Sell
4,102
-2,637
-39% -$25.3K ﹤0.01% 1561
2024
Q1 		$68.3K Buy
6,739
+3,769
+127% +$38.4K 0.01% 1208
2023
Q4 		$29.9K Buy
2,970
+2,177
+275% +$19.9K ﹤0.01% 1638
2023
Q3 		$7.43K Buy
793
+192
+32% +$2.74K ﹤0.01% 2068
2023
Q2 		$14.7K Sell
601
-1,357
-69% -$34.1K ﹤0.01% 1860
2023
Q1 		$45.6K Buy
1,958
+1,403
+253% +$35.9K ﹤0.01% 1287
2022
Q4 		$14K Sell
555
-415
-43% -$10.2K ﹤0.01% 1811
2022
Q3 		$19K Buy
970
+575
+146% +$14.6K ﹤0.01% 1589
2022
Q2 		$10K Buy
395
+324
+456% +$7.56K ﹤0.01% 1683
2022
Q1 		$2K Buy
71
+38
+115% +$1.13K ﹤0.01% 2205
2021
Q4 		$1K Sell
33
-36
-52% -$1.41K ﹤0.01% 2422
2021
Q3 		$3K Buy
69
+64
+1,280% +$2.77K ﹤0.01% 2081
2021
Q2 		$0 Buy
+5
New +$227 ﹤0.01% 2575

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Quadrant Capital Group's VIR Position: Q1 2026 in Review

Quadrant Capital Group held its Vir Biotechnology (VIR) position steady in Q1 2026 at 182 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #2534.

Quadrant Capital Group first reported a position in VIR in Q2 2021 and has held it in 18 quarters since. The position peaked at $68.3K in Q1 2024. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Quadrant Capital Group held 182 shares of Vir Biotechnology worth $1.63K as of Q1 2026.
  • Quadrant Capital Group left its Vir Biotechnology share count unchanged in Q1 2026.
  • Vir Biotechnology made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2534 holding.
  • Quadrant Capital Group first reported a position in Vir Biotechnology in Q2 2021 and has held it in 18 quarters since.
  • Quadrant Capital Group's Vir Biotechnology position peaked at $68.3K in Q1 2024.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.